Matrix protein compositions for induction of apoptosis

Details Matrix protein compositions for induction of apoptosis Matrix protein compositions for induction of apoptosis

2011-06-14

2011-06-14

Harris, Alana M (Department: 1643)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S001000, C514S001100, C514S019200, C514S019300

Reexamination Certificate

active

07960347

ABSTRACT:
Enamel matrix, enamel matrix derivatives and/or enamel matrix proteins or peptides may be used as therapeutic or prophylactic agents for inducing programmed cell death (apoptosis), in particular in the treatment or prevention of cancer or malignant or benign neoplasms.

REFERENCES:
patent: 4672032 (1987-06-01), Slavkin et al.
patent: 6503539 (2003-01-01), Gestrelius et al.
patent: 0263086 (1988-04-01), None
patent: 0337967 (1989-10-01), None
patent: WO 97/02730 (1997-01-01), None
patent: WO 99/43344 (1999-09-01), None
Scully, Robert E. Pathology of Ovarian Cancer Precursors. Journal of Cellular Biochemistry, Supplement 23: 208-218, 1995.
Pre-appeal Examination Report dated Sep. 7, 2010 in corresponding JP Application No. 2000-603685, with English language translation.
“Critical Reviews in Oral Biology & Medicine” Proteinases in Developing Dental Enamel, J.D. Bartlett and J.P. Simmer, Crit. Rev. Oral Biol. Med. 1999, pp. 425-441.
Vitale, M. et al., “Fibronectin is Required to Prevent Thyroid Cell Apoptosis through an Integrin-Mediated Adhesion Mechanism”, Endocrinol. Metab. 83 (10), 1998, pp. 3673-3680.
Zhang, Z. et al., “The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression”, Proc. Natl. Acad. Sci. USA 92 (13), 1995, pp. 6161-6165.
Kim, H. J. et al., “Integrin mediation of type II cell adherence to provisional matrix proteins”, Am. J. Physiol. 271 (2 pt. 1), 1996, pp. L277-L286.
McGill, G. et al., “Loss of Matrix Adhesion Triggers Rapid Transformation-Selective Apoptosis in Fibroblasts”, J. Cell Biol. 138 (4), 1997, pp. 901-911.
Mason, M. D. et al., “Adhesion molecules in melanoma—more than just superglue?”, J. R. Soc. Med. 89 (7), 1996, pp. 393-395.
Buckley, C.D. et al., “RGD peptides induce apoptosis by direct caspase-3 activation”, Nature 397, Feb. 1999, pp. 534-539.
Gestrelius et al., “In vitro studies on periodontal ligament cells and enamel matrix derivative”, J. Clinical Periodontology, 24:685 (1997).
Lyngstadaas et al., “Autocrine growth factors in human periodontal ligament cells cultured on enamel matrix derivative”, J. Clinical Periodontology, 28:181 (2001).
Kawase et al., “Cytostatic action of enamel matrix derivative (EMDOGAIN) on human oral sqamous cell carcinoma-derived SCC25 epithelial cells”, J. Periodont. Res. 35:291 (2000).
Cancer: Principles and Practice of Oncology, 5th edition, (Editors, Devita, Jr. et al. Lippincott-Raven Publishers, pp. 1433-1437, 1997).
Ruddon, Raymond W. Cancer Biology, third edition. New York: Oxford University Press, 1995.
Gura, T., “Systems for Identifying Drugs Are Often Faulty”, Science 278: 1041 and 1042, Nov. 7, 1997.

Affiliated with

Also associated with

Rating

Matrix protein compositions for induction of apoptosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Matrix protein compositions for induction of apoptosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Matrix protein compositions for induction of apoptosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2667480